Revive Therapeutics Ltd., a Toronto-based life sciences firm, has announced promising findings from a recent research study examining the effects of bucillamine in the context of nerve-agent exposure. Conducted by Defence Research and Development Canada (DRDC), the study utilized an established animal model to investigate bucillamine's safety and efficacy compared to N-acetylcysteine (NAC), which has previously been evaluated in similar studies.
The study focused on several critical endpoints, including clinical signs, seizure activity, and the preservation of GABA receptor signaling in the brain. Both bucillamine and NAC-treated animals showed comparable preservation of GABA receptor post-synaptic density when compared to control animals. However, a significant finding was that bucilamine-treated animals did not exhibit any instances of pulmonary hemorrhage, a side effect seen in those treated with NAC. No cerebral hemorrhage was reported in either treatment group.
Michael Frank, CEO of Revive Therapeutics, emphasized the study’s findings as a strong basis to further investigate bucillamine in the realm of nerve-agent countermeasures. Given the results, the company plans to explore additional opportunities for collaboration with government and defense organizations. Further confirmatory studies initiated by DRDC are scheduled to commence in the fourth quarter of 2026, focusing on bucillamine's implications for brain injury, oxidative stress, and respiratory function.
While the preliminary results are favorable, they are derived from animal models, necessitating further validation to accurately assess the effectiveness of bucillamine in humans and real-world scenarios. Revive Therapeutics is poised to continue its research journey in biodefense and pandemic preparedness with these findings paving the way for future inquiries.
The study conducted by Defence Research and Development Canada (DRDC) found that bucillamine demonstrated comparable effectiveness to N-acetylcysteine (NAC) in preserving GABA receptor signaling in an animal model of nerve-agent exposure. Notably, no pulmonary hemorrhage was observed in the bucillamine-treated group, while it was present in the NAC-treated group.
The results are significant as they suggest that bucillamine may have a safer profile compared to NAC, given that pulmonary hemorrhage was observed in the NAC-treated group and not in those treated with bucillamine. However, the presence of similar seizure activity in both groups indicates that further evaluation is necessary.
Revive Therapeutics intends to continue evaluating bucillamine's potential applications in biodefence and pandemic preparedness. Additional confirmatory studies by DRDC are scheduled to begin in Q4-2026, which will further investigate bucillamine’s effects on brain injury, oxidative stress, and respiratory function.
The research on bucillamine is being conducted by Defence Research and Development Canada - Suffield Research Centre (DRDC), in collaboration with Revive Therapeutics Ltd. (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), which focuses on biodefence and pandemic preparedness therapeutics.
Revive Therapeutics aims to explore the potential role of bucillamine in biodefence and pandemic preparedness through further research and potential collaborations with government and strategic organisations, based on the findings from the initial study.
Bucillamine appeared to preserve GABA receptor function comparable to NAC, while avoiding the pulmonary hemorrhage side effect that was observed in the NAC group. However, both groups displayed similar signs of seizure activity, indicating that the response to nerve-agent exposure may be similar in some respects.
While the study presents positive results for bucillamine, potential risks include the need for further validation through additional studies, as the current research is in an animal model. The effects and safety of bucillamine in humans or real-world scenarios are not established based on this study alone.
According to the announcement, additional confirmatory studies on bucillamine by DRDC are scheduled to begin in Q4-2026.